356 related articles for article (PubMed ID: 28436987)
1. Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes.
Wang YK; Bashashati A; Anglesio MS; Cochrane DR; Grewal DS; Ha G; McPherson A; Horlings HM; Senz J; Prentice LM; Karnezis AN; Lai D; Aniba MR; Zhang AW; Shumansky K; Siu C; Wan A; McConechy MK; Li-Chang H; Tone A; Provencher D; de Ladurantaye M; Fleury H; Okamoto A; Yanagida S; Yanaihara N; Saito M; Mungall AJ; Moore R; Marra MA; Gilks CB; Mes-Masson AM; McAlpine JN; Aparicio S; Huntsman DG; Shah SP
Nat Genet; 2017 Jun; 49(6):856-865. PubMed ID: 28436987
[TBL] [Abstract][Full Text] [Related]
2. A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.
Dong F; Davineni PK; Howitt BE; Beck AH
Cancer Epidemiol Biomarkers Prev; 2016 Nov; 25(11):1511-1516. PubMed ID: 27496093
[TBL] [Abstract][Full Text] [Related]
3. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.
George J; Alsop K; Etemadmoghadam D; Hondow H; Mikeska T; Dobrovic A; deFazio A; ; Smyth GK; Levine DA; Mitchell G; Bowtell DD
Clin Cancer Res; 2013 Jul; 19(13):3474-84. PubMed ID: 23633455
[TBL] [Abstract][Full Text] [Related]
4. Genomic mutation features identify distinct BRCA-associated mutation characteristics in endometrioid carcinoma and endometrioid ovarian carcinoma.
Cao C; Yu R; Gong W; Liu D; Zhang X; Fang Y; Xia Y; Zhang W; Gao Q
Aging (Albany NY); 2021 Nov; 13(22):24686-24709. PubMed ID: 34837690
[TBL] [Abstract][Full Text] [Related]
5. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
[TBL] [Abstract][Full Text] [Related]
6. Involvement of pelvic inflammation-related mismatch repair abnormalities and microsatellite instability in the malignant transformation of ovarian endometriosis.
Fuseya C; Horiuchi A; Hayashi A; Suzuki A; Miyamoto T; Hayashi T; Shiozawa T
Hum Pathol; 2012 Nov; 43(11):1964-72. PubMed ID: 22626277
[TBL] [Abstract][Full Text] [Related]
7. The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy.
Chui MH; Ryan P; Radigan J; Ferguson SE; Pollett A; Aronson M; Semotiuk K; Holter S; Sy K; Kwon JS; Soma A; Singh N; Gallinger S; Shaw P; Arseneau J; Foulkes WD; Gilks CB; Clarke BA
Am J Surg Pathol; 2014 Sep; 38(9):1173-81. PubMed ID: 25025451
[TBL] [Abstract][Full Text] [Related]
8. The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2.
Gu Y; Zhang M; Peng F; Fang L; Zhang Y; Liang H; Zhou W; Ao L; Guo Z
Oncotarget; 2015 Feb; 6(4):2397-406. PubMed ID: 25537514
[TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population.
Sekine M; Nagata H; Tsuji S; Hirai Y; Fujimoto S; Hatae M; Kobayashi I; Fujii T; Nagata I; Ushijima K; Obata K; Suzuki M; Yoshinaga M; Umesaki N; Satoh S; Enomoto T; Motoyama S; Tanaka K;
Clin Cancer Res; 2001 Oct; 7(10):3144-50. PubMed ID: 11595708
[TBL] [Abstract][Full Text] [Related]
10. Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma.
Howitt BE; Hanamornroongruang S; Lin DI; Conner JE; Schulte S; Horowitz N; Crum CP; Meserve EE
Am J Surg Pathol; 2015 Mar; 39(3):287-93. PubMed ID: 25581732
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 and BRCA2 mutation type associated with cancer risk.
Burki TK
Lancet Oncol; 2015 May; 16(5):e205. PubMed ID: 25892146
[No Abstract] [Full Text] [Related]
12. Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy.
Chen P; Huhtinen K; Kaipio K; Mikkonen P; Aittomäki V; Lindell R; Hynninen J; Auranen A; Grénman S; Lehtonen R; Carpén O; Hautaniemi S
Cancer Res; 2015 Aug; 75(15):2987-98. PubMed ID: 26122843
[TBL] [Abstract][Full Text] [Related]
13. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
14. BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in non-familial cases.
Yazici H; Glendon G; Yazici H; Burnie SJ; Saip P; Buyru F; Bengisu E; Andrulis IL; Dalay N; Ozcelik H
Hum Mutat; 2002 Jul; 20(1):28-34. PubMed ID: 12112655
[TBL] [Abstract][Full Text] [Related]
15. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT
Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513
[TBL] [Abstract][Full Text] [Related]
16. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome.
Wang ZC; Birkbak NJ; Culhane AC; Drapkin R; Fatima A; Tian R; Schwede M; Alsop K; Daniels KE; Piao H; Liu J; Etemadmoghadam D; Miron A; Salvesen HB; Mitchell G; DeFazio A; Quackenbush J; Berkowitz RS; Iglehart JD; Bowtell DD; ; Matulonis UA
Clin Cancer Res; 2012 Oct; 18(20):5806-15. PubMed ID: 22912389
[TBL] [Abstract][Full Text] [Related]
17. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
18. Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer?
Kauff ND
J Clin Oncol; 2008 Jan; 26(1):9-10. PubMed ID: 18165631
[No Abstract] [Full Text] [Related]
19. Failure of BRCA1 dysfunction to alter ovarian cancer survival.
Buller RE; Shahin MS; Geisler JP; Zogg M; De Young BR; Davis CS
Clin Cancer Res; 2002 May; 8(5):1196-202. PubMed ID: 12006538
[TBL] [Abstract][Full Text] [Related]
20. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]